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The effects of arsenic on cells and organisms  of various kinds depend to a 
considerable extent on the structure of the compound in which the arsenic is in- 
corporated, as Ehrlich showed many years ago (1, 2). More recent studies have 
shown further that certain arsenicals act powerfully in vitro on microbial cells 
of various species and on several kinds of proliferating mammalian cells as well 
(3, 4); and that arsenicals sometimes inhibit temporarily and to a slight extent 
the growth of certain tumor cells (5, 6), though amounts of arsenicals  that are 
readily tolerated by a given host usually have little or no enduring effect on its 
proliferating neoplastic ceils (7-11).  When arsenic is suitably combined with 
protein by means of the azo linkage,  however, its effectiveness in inhibiting the 
growth of a number of transplanted mouse lymphomas, particularly Lymphonm 
6C3HED, is greatly enhanced; indeed, small  quantities of arsenic azoproteins 
will often bring about the complete regression of large 6C3HED lymphomas in 
adult C3H mice without proving notably toxic for the latter (12). 
In further studies of arsenic azoproteins as antilymphoma agents, we have 
recently found that 4-arsonophenylazoproteins act as powerful anticoagulants 
under a variety of conditions in vivo and in vitro, while ordinary inorganic  and 
organic  arsenicals  and  other  arsenic-containing  eompounds,--for  example, 
those in which arsenic is joined to amino acids or peptides through  the azo 
linkage,  or  to  proteins  through  couplings  other  than  the  azo  linkage,--are 
largely devoid of ability to inhibit the coagulation of blood. Further,  arsenic- 
containing  compounds that  act  strongly as anticoagulants  also act strongly 
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against Lymphoma  6C3HED  cells in  v/~o,  as  direct  comparisons  have  now 
shown; while conversely, arsenic-containing compounds that are devoid of anti- 
coagulant activity are also devoid of ability to act upon the lymphoma cells in 
vivo. 
The findings, given in detail in this paper, provide basis for the supposition 
that arsenic  azoproteins  may  give  rise  to  anticoagulant and antilymphoma 
effects through similar or related mechanisms.  This possibility is explored 
further in an associated paper. 
Materials  and Methods 
Azoproteins were prepared  by standard  methods as previously described  (12,  13,  14). 
Diazotates  were  obtained from  the  following  substances: arsanilic acid,  p-aminopheayl- 
arseae  oxide,  sulfanilic acid,  p-aminobeazoic acid,  p-pheayleaediamine (as  described  by 
Sannders, reference 15), and aniline. In most experiments these substances were conjugated 
with bovine alb,,mln (Armour Pharmaceutical Company, Kankakee, Illinois, Coim's fraction 
V) but on some occasions human albumin and human globulin (Merck and Company Inc., 
Rahway, New Jersey), were used. 
By varying the proportions of diazotate and protein in the reaction mixture, azoproteins 
with different degrees of conjugation were obtained as shown by the analysis for arsenic and 
sulfur in the snifonic  groups (performed by Schwartzkopf Microanalytical  Laboratories, Wood- 
side,  New York). To produce 4-arsonophenylazoproteins  with 3 to 4 per cent As content 1 
millimole of diazotate was used for each gram of protein. Conjugation was usually performed 
at pH 9.0 and 0-4°C. After 2 or more hours the pH of the reaction mixture was adjusted to 6.5 
and the azoprotein was then freed from other reaction products by dialysis against water for 
48 hrs. 
In the case of compounds with a very high content of arsenic (more than 7 per cent), the 
azoprotein after dialysis was reacted with diazotate once or twice more. Final products were 
lyophilized. 
The degree of conjugation in unsubstituted phenylazoprotein and 4-carboxypheaylazopro- 
tein, could not be determined by direct analysis, but the substances used in the present experi- 
meats were prepared using similar amounts of reactants and similar conditions to those em- 
ployed in preparing 4-arsonopheaylazoproteins  with 3 to 4 per cent As content. As described 
previously, the resulting azoproteins in solution gave similar extinction coefficients when opti- 
cal density readings were made (14). 
Arsenic protein conjugates were prepared in two other ways. First, bovine albumin was 
conjugated with p-chloracetyl aminophenylarsonic acid (kindly prepared by Dr. Charles C. 
Price of the Department of Chemistry, University of Pennsylvania by the method of Giemsa 
and Tropp, reference 16). 1 gm of this substance was dissolved in 100 ml 0.2 x¢ PO4 buffer at 
pH 8.0 containing 10 gm bovine albumin and 0.1 gm potassium iodide and the pH restored to 
8.0 by the addition of 0.2 N NaOH. The solution was sterilized by passage through a  Seitz 
filter and left at 37°C for 8 days, dialyzed against water for 72 hours, and the protein finally 
lyophillzed.  The potassium iodide acted as a catalyst, greatly increasing the reaction velocity 
as shown by estimation of the chloride ion liberated and by the content of arsenic in the final 
protein preparations. 
Further arsenic-protein  conjugates were obtained using p-(2-4 dichioro-s-triazinyl) amino- 
phenylarsonic acid prepared according to Friedheim (17). Reaction conditions were similar to 
those employed with p-chloracetyl aminophenylarsonie acid but a  0.25  ~  bicarbonate-COs 
buffer at pH 7.3 was used and the iodide catalyst omitted. j.  D.  BROOME  AND  ~'OHN  G.  KIDD  451 
4-Arsonophenylazopeptones  were prepared in a manner similar to that used for the corre- 
sponding azoproteins, using commercially available peptones (Difco Laboratories, Inc., De- 
troit). Azopeptones were precipitated from the reaction mixture at pH 9.0 by the addition of 
6 volumes of ethanol, dissolved in water, and reprecipitated, the process being repeated three 
times. The azopeptones  were finally lyophillzed  from aqueous solution at pH 7.0. 
The formation of 4-arsonophenylazo  derivatives of amino acids has been described by 
Pauley (18) whose method has been followed in essentials in the present experiments.  The 
structure of these derivatives has recently been discussed by Tabachnick and Sobotka (19). 
4-Arsenophenylazotyrosine  was  prepared  by slowly  adding  an  equimolecular  amount  of 
diazotised arsanilic acid (pH 8.0) to a 1 per cent aqueous suspension of n-tyrosine (Merck and 
Co.). The pH of the reaction mixture was maintained at 9.5 and 10.0 by addition of ~ Na0H 
and the temperature at 0--6°C. L-Tyrosine rapidly and completely dissolved. After 2 hours, the 
solution was acidified to pH 3.0. A brown precipitate formed which was collected by centrifu- 
gation, and supernatant being discarded. The precipitate was dissolved by raising the pH to 
9.0 and precipitated  by acidification  on two further occasions after discarding the supernatants. 
The material  was finally  dissolved at pH 7.0 and lyophilized. 
4-Arsonophenylazohistidine  was  prepared  from  r-histidine  (Nutritional  Biochemicals 
Corporation, Cleveland, Ohio) in a similar manner. 
Blood Coagulation Experiments.--Rabbit blood was obtained by cardiac puncture. Human 
blood was obtained by venipuncture and anticoagulated by adding 9 volumes of blood to 1 
volume of 3.8 per cent sodium citrate solution. Plasma from freshly obtained blood was used 
in all experiments; it was separated by centrifugation at 3000 m,  zt for 15 minutes at tempera- 
tures of 3-4°C. Thrombin used was topical preparation of Parke Davis and Company, De- 
troit. 
Blood clotting times were measured by the method of Lee and White (20). Plasma recalci- 
fieation times were measured by modifications of the method of Biggs and MeFarlane (21), as 
described in the text. 
Implant~ion of Lymphoma 6C3ttED in ZBC Mice.--The  techniques used have been de- 
scribed previously (12, 22). 
RESULTS 
Anticoagulant Effects of 4-Arsonophenylazoproteins  in Vivo.--In  experiments 
undertaken for other purposes, rabbits were given intravenous injections of a 4- 
arsonophenylazoalbumin containing 6.5 per cent As. Several of the animals that 
received more than 10 mg As/kg died within 24 hours following the injections. 
Surprisingly, at autopsy 6 or more hours after death, the blood of these rabbits 
was  everywhere  uncoagulated;  furthermore,  fibrinolysis had  plainly not  oc- 
curred, since the blood eventually became fully coagulated when it remained for 
some time in contact with tissues cut in the dissection. 
About this time, a similar anticoagulant effect was observed in mice. A group 
of 8  mice weighing approximately 25  gm were  given a  single intraperitoneal 
injection of 4-arsonophenylazoalbumin containing 6.5 per cent of arsenic, in a 
dosage of 1 mg As  per mouse; following this a  toe was cut for identification 
purposes in the manner used as routine in this laboratory. These animals bled 
profusely from the small wound produced,--indeed to the extent that all died 
exsanguinated  in  the  following  24  hours.  Untreated  control  mice  remained 
healthy and as usual their toes ceased to bleed after a few minutes. 452  ARSENIC  AZOPROTEINS.  I 
Further experiments  were performed to define the anticoagulant effect more 
precisely. First, estimations were made of whole blood clotting time in rabbits 
given the same arsenic azoprotein preparation as that used in the experiments 
already mentioned. Control blood samples were obtained from these rabbits by 
means of a clean cardiac puncture, and the clotting times were determined. The 
animals were then injected intravenously with various quantities  of  the  azo- 
protein;  after  5  minutes  a  further  cardiac puncture  was  performed  and  the 
TABLE I 
Dday in Whole Blood Clotldng Time of Rabbits Given 4-Arsonophenytagoalbumin 
Intravenously 
Dosage  Clotting time 
Rabbit 
10 
11 
Arsa- 
nilate* 
4-Arsono- 
phenylazo- 
albumin~ 
m/kg  mg/kg 
14.5 
72.5  -- 
174.0 
15.5 
38.4 
77.5 
•  --  .  115.2 
•  --  •  115.0 
•  --  • 310.0 
--  620.0 
--  930.0 
As 
mg/kg 
5.0 
25.0 
50.0 
1.0 
2.5 
5.0 
7.5 
10.0 
20.0 
40.0 
50.0 
Before 
treatment 
rain.  sec. 
2  48 
3  9 
1  5 
3  26 
3  14 
3 
3  24 
55 
1  30 
1  56 
5 rain. after intraveneous injection 
of test substance 
mln.  Se¢, 
3  20 
3  5 
2  8 
6  15 
8  55 
14  23 
23  30 
45 
Beginning at 3 hrs. complete by 18 
hrs. 
Beginning at 6 hrs. complete by 24 
hrs. 
Uncoagulated after 24 hrs. 
Market bought rabbits weighing 3.0 to 4.5 kg were used. Clotting  times were measured 
by the method  of Lee and White  (20). 
* 3 gm per cent arsanilate with 20 gm per cent bovine albumin, pH 7.0. 
20 gin per cent aqueous solution of 4-arsonophenylazoalbumin M9 (As 6.5 per cent). 
dotting time again measured.  Table I  shows the results; these dearly confirm 
the  earlier  in  viw  observations.  An anticoagulant  effect was produced  when 
15.5 nag of the azoprotein/kg was given, and at higher dosage levels the anti- 
coagulant effect increased progressively. However, it was not until 930 mg/kg 
was reached that the blood became completely incoagulable. No anticoagulant 
effect was observed in controls given arsanilic acid and protein mixtures, even 
though amounts  of azoproteins with  similar  arsenic  content  were powerfully 
anticoagulant. 
Anticoagulant  Effects of 4-Arsonophenyla~oproteins  in  Vitro.--Human  plasma 
proved  to  be  particularly  sensitive  to  the  anticoagulant  effects  of 4-arsono- J.  D.  BROOME  AND  JOHN  G.  KIDD  453 
phenylazoproteins. Table II shows that, with the same azoprotein preparation 
as that used in the previous experiment, an anticoagulant effect was demon- 
strable at a concentration as low as 0.1 mg azoprotein per ml, rising progressively 
above this. Other preparations of azoproteins with widely differing content of 
azo groups and of arsenic also produced anticoagulant effects, but according to 
a particular pattern. It will be seen from the experiment shown in Table III, 
that the anticoagulant effect of azoalbumlns increased progressively with their 
content of arsenic, to approximately 7.4 per cent. Above this level, increased 
arsenic content had either a negligible effect in increasing anticoagulant activity, 
or indeed might actually produce a  less effective substance, as for example, 
TABLE II 
Delay in the Clotting Time of Human Plasma Produced by 
4-Arsonophenylazoalbumin in Vitro 
Clotting mixture: 0.4 ml plasma -k" 0.01 ml of azoprotei~  Clotting times after recallilcafion with 
solutions  producing  the following con- 
centrations  0.25 ml of 0.05 M CaCls 
rag~ha 
Nil (control) 
0.10 
0.19 
0.38 
0.75 
1.50 
m~.  .~e.~, 
2  58 
3  30 
5  4O 
10  30 
15  45 
4O 
The 4-arsonophenylazoalbumin  M9 (6.5 per cent As) was used, dissolved  in 0.9 gm per 
cent  sodium chloride (pH 7.1). 
material M8 containing 17 per cent As. It will be further seen that the two 4- 
arsonophenylazoglobulins were  considerably less  effective as  anticoagulants 
than azoalbumins of corresponding arsenic content. 
The  Relationship  of Structure  to  Anticoagulant  Activity Amongst  4-Arsono- 
phenylazoproteins  and  Chemically  Related  Substances.--The  structure  of a  4- 
arsonophenylazoprotein may be illustrated in the following way, where tyrosine 
in the protein forms the site of attachment of the azo group. 
OH 
O~~N~N--Protein 
OH 
A  B  C 
Azo groups are also joined to the protein molecule through the ring structures of 
tryptophane and histidine, through sulfhydryl groups,  and possibly through 
other sites (Howard and Wild, reference 23). 454  ARSENIC AZOPROTEINS. I 
Analogues of 4-arsonophenylazoprotein were prepared by varying the groups 
at A, B,  and C.  At A  the arsonic group was replaced,  (a)  by acidic groups, 
namely, carboxylic, sulfonic and arsinoso (trivalent arsenic);  (b) by the basic 
amino group, and  (c)  by hydrogen, forming unsubstituted  phenylazoprotein. 
The azo group indicated at B was replaced by carbamoylmethyl and triazinyl 
groups in two further conjugates. These protein conjugates were prepared by 
alkylation, and hence free amino groups, phenolic hydroxyl groups, and sulf- 
TABLE III 
The Effectiveness  of 4-Arsonophenflazopro~'in  Preparations with Differing Arsenic 
Contents as Anticoagulants in Vitro 
Clotting mixture: 0.4 ml citrated plasma +  0.01 ml of the azoprotein solutions, each 
of 5 gm per cent. 
Azoprotein solutions 
Protein 
$onrce~ 
serum 
Designation 
of conjugate 
As content 
of conjugate 
Clotting times after 
recalcification 
with 0.25 ml 
of 0.05 M  CaClt 
Control, 0.9  gin  per  cent 
NaC1 
4-Arsonophenylazo- 
albumins 
4-Arsonophenylazoglobulin  s 
Hul~an 
Bovine 
Bovine 
Bovine 
Human 
Bovine 
Human 
Human 
Human 
Kll 
K6 
K13 
K1 
Mll 
K3 
M8 
M12 
M13 
#er ce~ 
0.2 
0.8 
1.9 
5.5 
7.4 
15.7 
17.0 
1.9 
7.5 
mln.  sec. 
2  5O 
2  40 
3  10 
4  23 
12  45 
17 
19  30 
8  15 
3  20 
8  10 
Other tests performed using  0.01 ml of 5 gm per cent bovine albumin with arsanilic acid in 
concentrations of 1.0, 2.0, and 3.0 gm per cent (pH 7.0) produced no anticoagulant effect by 
comparison with the 0.9 gm per cent NaC1 control. 
hydryl groups of the protein would be expected to form sites of attachment (24). 
At C, instead of using whole protein, polypeptides, and amino acids were used. 
Table IV shows the results of testing the effect of a number of the compounds 
described on the clotting times of recalcified human plasma. It will be seen that 
as before, 2 different preparations of 4-arsonophenylalbumin produced a  clear 
anticoagulant effect, and so too, though less effectively in relation to its arsenic 
content,  did  a  preparation  of 4-arsinosophenylazoprotein.  Other  acidic  azo- 
proteins also produced a strong anticoagulant effect, indeed, a 4-sulfonophenyl- 
azoalbumin preparation gave the strongest anticoagulant effect of any of the 
substances tested;  the 4-carboxyphenylazoalbumin produced an anticoagulant 
effect only slightly less strong that that of the 4-arsonophenylazoalbumin M9. j.  D.  BROOME  AND  JOHN  G.  KIDD  455 
None of the other substances tested showed anticoagulant activity, it being 
especially noteworthy that the protein conjugates of phenylarsonic acid which 
lacked the azo group were without effect.  4-Arsonophenylazo  compounds of 
peptones were likewise devoid of anticoagulant effect, despite their high arsenic 
content.  Clearly amongst the substances tested considerable  structural speci- 
ficity was required for anticoagulant activity. Active substances, it can be seen, 
(a)  were proteins,  (b) possessed a  high negative charge,  and  (c)  their  acidic 
groups were linked to protein through azo bonds. 
Structural Requirements for Antilymphoma Activity.--The general features of 
the inhibitory effects of 4-arsonophenylazoproteins on the growth of lymphomas 
in vivo have been fully described by Kidd (12). Lymphoma 6C3HED was shown 
to be particularly sensitive to these substances; using a sufficient dosage of 4- 
arsonophenylazoprotein,  and one not appreciably toxic to the host, complete 
regression  of fully established tumors 1 to 2 cm in diameter could be regularly 
produced. 
In the present experiments, the antilymphoma activity of a number of differ- 
ent  4-arsonophenylazoprotein  preparations  and  of  other  chemically  related 
substances was assayed in a standardized way that gave a particularly sensitive 
and sharp end point. Small numbers of Lymphoma 6C3HED cells (50 thousand) 
were implanted into groups of ZBC mice subcutaneously in each flank.  A suit- 
able number of implanted animals were kept as controls,  others were treated 
with the substances under test within 2 hours of implantation and on some oc- 
casions treatment was also given on the succeeding  2 days. In control animals, 
tumors appeared regularly on the 9th to llth days following implantation. By 
careful daily examination, delay in tumor appearance brought about by treat- 
ment could be readily detected. As will be shown,  small, non-toxic quantities 
of 4-arsonophenylazoprotein produced complete suppression of tumor growth. 
The properties of a number of different 4-arsonophenylazoproteins in suppress- 
ing tumor growth are shown in Table V. It will be seen that 4-arsonophenylazo- 
proteins with arsenic content from 0.2  to 5.5 per cent were all highly active 
in inhibiting  tumor  growth;  single  injections containing  0.5  to  0.75  mg  As 
brought about complete tumor suppression.  But, as with their anticoagulant 
activity, substances with higher arsenic content, had less tumor inhibiting ac- 
tivity. Thus, the azoalbumin K4, containing 7.6 per cent As, produced complete 
tumor suppression only in a dose of 1.0 mg As, while 2 other preparations con- 
taining  15.7 and 17.0 per cent As required to be given in doses of 3.0 mg As, 
before tumor suppression occurred. Again,  azoglobulins  were rather less effec- 
tive as tumor inhibitory agents than were azoalbumins of equal arsenic content; 
for instance, it was necessary to inject azoglobulin  containing 7.5 per cent As 
in a dosage of 2.0 mg As to produce complete tumor inhibition, whereas only 1.0 
mg As was required for a similar azoalbumin. Analogues of 4-arsonophenylazo- 
proteins containing trivalent arsenic (derived from 4-aminophenylarsene oxide) 
inhibited tumor growth, but, as shown in Chart 1, they did this considerably less 456 
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powerfully in relation to their arsenic content than did 4-arsonophenylazopro- 
teins.  The  tumor  inhibitory  activity of  these  substances  thus  corresponded 
closely with their effects on  the coagulation process. 
Further  experiments soon made  it clear that  anticoagulant activity per se 
was not necessarily associated with the ability to inhibit tumor growth. Chart 2 
shows that although 13 mg of a preparation of 4-arsonophenylazoprotein caused 
complete tumor supression in three animals, considerably larger quantities of 4- 
TABLE V 
The Arsenic Content of 4-Arsonophenylazoproteins in Relation to Their Tumor 
Inhibitory A ctivity 
Identity of 4-arsonophenylazoprotein 
tested 
Azo-bovine albumin Kll 
"  "  K6 
"  "  K5 
"  "  K17 
"  "  K13 
"  "  K1 
"  "  K4 
"  "  K3 
.~zo-human  "  M8 
"  globulin M12 
"  "  M13 
As content of 
azoprotein 
#er ce~J 
Curative dose 
of azoprotein 
mg 
0.2  250.0 
0.8  62.5 
1.0  50.0 
2.0  25.0 
2.5  20.0 
5.5  9.1 
7.6  9.9 
15.7  19.1 
17.0  18.0 
1.9  26.3 
7.5  10.0 
Curative quantity 
of arsenic 
mg 
0.75 
0.50 
0.50 
0.50 
0.75 
0.50 
1.00 
3.00 
3.00 
1.00 
2.0 
The method used was as follows: groups of 3 ZB  C mice were implanted  with 50,000 6C3HED 
cells in each flank. 30 to 60 minutes later these animals were injected intraperitoneally with 
azoprotein solutions to provide a dosage of 0.25, 0.50, 0.75, and 1.00 mg As. With K3 and 
M8 the dosages used were 0.5, 1.0, 2.0, 3.0 mg As. The curative dose represents the minimum 
dose which caused complete suppression of tumor growth in a group of three mice, estimated at 
30 days following implantation. Tumors appeared in untreated control mice 9 days follow- 
ing implantation, causing death 16 to 20 days later. 
sulfonophenyl- and 4-carboxyphenylazoproteins, which were even more effective 
as anticoagulants  (see Table IV), produced no significant inhibition of tumor 
growth. The doses of these substances were the maximum which could be given 
and were in several cases notably toxic. Phenylazoalbumin and 4-aminophenyl- 
azoalbumin were similarly ineffective. The essential role of arsenic in bringing 
about tumor inhibition is further shown by the ability of dimercaprol (BAL) 
to reverse the antilymphoma effects of 4-arsonophenylazoproteins. 
The E~ect of BAL  on the Antilymphoma Activity of 4-Arsonophenylazoprotein. 
--Earlier experiments have shown that 0.25 to 0.5 mg arsenic contained in the 
most effective 4-arsonophenylazoprotein preparations brought about the com- 
plete suppression of tumors in animals newly implanted with cells of Lymphoma 0 
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6C3HED. The effect of BAL simultaneously administered with azoprotein was 
examined in a number of experiments of which Chart 3 shows a representative 
result. It is clear that BAL while itself failing to influence the growth rate of 
the tumors is able to render entirely ineffective a  quantity of 4-arsonophenyl- 
azoprotein containing 1.0 mg As. Alone, half this amount completely inhibited 
tumor growth and even one-quarter produced a detectable inhibition. 
This experiment shows a  further point which will be  discussed more fully 
later, namely that since BAL reacts only with trivalent arsenic, the fact that it 
protects lymphoma cells  against inhibition by 4-arsonophenylazoproteins, in- 
dicates that the As in these effective preparations must first be reduced before 
producing its cytotoxic effects. 
The Dependence of Tumor Inhibitory Activity of Arsenic Protein Conjugates on 
the Azo Linkage and on Molecular Size.--Proteins to which phenylarsonic acid 
was joined through methylcarbamoyl or triazinyl groups were previously shown 
to lack anticoagulant activity. Similar results, and again in contrast to the azo- 
proteins  were  found when these  substances  were  tested against Lymphoma 
6C3HED. Chart 4 shows that although 0.25 mg As given as azoprotein caused 
complete tumor suppression in each treated mouse,  in other animals 3  daily 
injections each of 1 mg As from both carbamoylmethyl and triazinyl proteins 
had relatively little or no tumor inhibitory effect. 
Preparations of 4-arsonophenylazopeptones were tested in the same manner 
by treatment of the hosts immediately following tumor cell implantation. It 
will be seen in Chart 5 that a preparation of azopeptone, containing 9.9 per cent 
As, produced no more than a slight delay in the appearance of the tumors, even 
though the dose of arsenic given, 2.5 mg, is the highest which toxicity tests have 
shown to be tolerated without a high mortality. 
Preparations of azo derivatives of L-tyrosine and L-histidine were also largely 
devoid of inhibitory effect on the tumor when given in the maximum tolerated 
amounts; again the quantities of arsenic they contained were considerably in 
excess of those which as azoprotein bring about complete tumor suppression. 
S~R¥  AND  COM'M'ENT 
Experiments given in this paper have shown that 4-arsonophenylazoproteins 
possess  marked  anticoagulant  activity both  in  vivo and  in vitro. Mice  and 
rabbits given moderate amounts of the arsenic azoprotein, for example, often 
bled to death from injuries that proved trivial in control animals, and their 
blood remained liquid during many hours' postmortem even when left in con- 
tact with transected tissues, fibrinolysis having no part in the outcome. So, too, 
the addition of minute amounts of 4-arsonophenylazoprotein to plasma pro- 
cured from citrated rabbit or human blood greatly prolonged the time required 
for clotting after recalcification. 
Other arsenic-containing compounds,--for example, those in which arsenic .E 
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was joined to amino acids or peptides through the azo linkage, or to proteins 
through couplings other than the azo linkage,--were largely devoid of anti- 
coagulant and antilymphoma effects. The findings as a whole show dearly that 
the structural requirements for anticoagulant and anfilymphoma effects  are: 
(a) possession of negatively charged arsouic or arsinoso groups, (b) large molecu- 
lar size (protein), and (c) linkage of arsenic-containing groups to protein through 
the azo bond. 
Two  acidic  azoproteins  that were  devoid of  arsenic,--namely 4-carboxy- 
phenylazoprotein and 4-sulfonophenylazoprotein,--were also  found  to  have 
marked anticoagulant effects in ~itro, but they had no inhibitory action against 
cells of Lymphoma 6C3HED  in vivo, even when they were given to mice in 
maximum tolerated amounts. The essential part played by arsenic in the anti- 
lymphoma activity of arsenic azoproteins was further emphasized by the action 
of dimercaprol  (BAL)  in preventing  the antilymphoma effects of 4-arsono- 
phenylazoprotein on Lymphoma 6C3HED cells in vivo. 
In an associated paper  the anticoagulant and antilymphoma effects of 4- 
arsonophenylazoproteins are studied further, and consideration is given to the 
ways in which these effects may be brought about. 
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